bioRxiv preprint doi: https://doi.org/10.1101/441261; this version posted January 3, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

1 Hidden 'risk' in polygenic scores: clinical use today could exacerbate health

- 2 disparities
- 3
- 4 Alicia R. Martin^{1,2,3}, Masahiro Kanai^{1,2,3,4,5}, Yoichiro Kamatani^{5,6}, Yukinori Okada^{5,7,8},
- 5 Benjamin M. Neale^{1,2,3}, Mark J. Daly^{1,2,3,9}
- 6
- ⁷ ¹ Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston,
- 8 MA 02114, USA
- ⁹ ² Program in Medical and Population Genetics, Broad Institute of Harvard and MIT,
- 10 Cambridge, MA 02142, USA
- ³ Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT,
- 12 Cambridge, MA 02142, USA
- ⁴ Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115,
- 14 USA
- ⁵ Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences,
- 16 Yokohama 230-0045, Japan
- ⁶ Kyoto-McGill International Collaborative School in Genomic Medicine, Graduate
- 18 School of Medicine, Kyoto University, Kyoto 606-8507, Japan
- ⁷ Department of Statistical Genetics, Osaka University Graduate School of Medicine,
- 20 Suita 565-0871, Japan
- ⁸ Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-
- IFReC), Osaka University, Suita 565-0871, Japan

- ⁹ Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki,
- 24 Finland
- 25
- 26 Abstract
- 27

28 Polygenic risk scores have the potential to improve health outcomes for a variety of 29 complex diseases and are poised for clinical translation, driven by the low cost of 30 genotyping (<\$50 per person), the ability to predict genetic risk of many diseases with a single test, and the dramatically increasing scale and power of genetic studies that aid 31 32 prediction accuracy. However, the major ethical and scientific challenge surrounding 33 clinical implementation is the observation that they are currently of far greater predictive 34 value in European ancestry individuals than others. The better performance of such risk 35 scores in European populations is an inescapable consequence of the heavily biased 36 makeup of genome-wide association studies, with an estimated 79% of participants in 37 all these existing studies being of European descent. Empirically, polygenic risk scores 38 perform far better in European populations, with prediction accuracy reduced by approximately 2- to 5-fold in East Asian and African descent populations, respectively. 39 40 This highlights that—unlike specific clinical biomarkers and prescription drugs, which 41 may individually work better in some populations but do not ubiquitously perform far 42 better in European populations-clinical uses of prediction today would systematically 43 afford greater improvement to European descent populations. Early diversifying efforts, 44 however, show promise in levelling this vast imbalance, even when non-European 45 sample sizes are considerably smaller than the best-powered studies to date. Polygenic

risk scores provide a new opportunity to improve health outcomes for many diseases in
all populations, but to realize this full potential equitably, we must prioritize greater
inclusivity of diverse participants in genetic studies and open access to resulting
summary statistics to ensure that health disparities are not increased for those already
most underserved.

51

Keywords: health disparities, genetic risk prediction, polygenic risk scores, diversity,
population genetics, statistical genetics

54

55 Polygenic risk scores (PRS), which predict complex traits using genetic data, are of 56 burgeoning interest to the clinical community as researchers demonstrate their growing 57 power to improve clinical care, genetic studies of a wide range of phenotypes increase 58 in size and power, and genotyping costs plummet to less than US\$50. Many earlier 59 criticisms of limited prediction power are now recognized to have been chiefly an issue 60 of insufficient sample size, which is no longer the case for many outcomes ¹. For example, polygenic risk scores alone already predict breast and prostate cancer risk in 61 European descent patients more accurately than current clinical models ²⁻⁴. Additionally, 62 63 integrated models of PRS together with other lifestyle and clinical factors have enabled 64 clinicians to more accurately quantify the risk of heart attack for patients; consequently, 65 they have more effectively targeted the reduction of LDL cholesterol and by extension 66 heart attack by prescribing statins to patients at the greatest overall risk of cardiovascular disease ⁵⁻⁹. Promisingly, return of genetic risk of complex disease to at-67 68 risk patients does not induce significant self-reported negative behavior or psychological

function, and some potentially positive behavioral changes have been detected ¹⁰. While 69 70 we share enthusiasm about the potential of PRS to improve health outcomes through 71 their eventual routine implementation as clinical biomarkers, we consider the consistent 72 observation that they are currently of far greater predictive value in individuals of recent 73 European descent than in others to be the major *ethical* and *scientific* challenge 74 surrounding clinical translation and, at present, the most critical limitation to genetics in 75 precision medicine. The scientific basis of this imbalance has been demonstrated in 76 population genetics simulations, theoretically, and empirically across many traits and diseases ¹¹⁻²². 77

78

79 All studies to date using well-powered genome-wide association studies (GWAS) to 80 assess the predictive value of PRS in European and non-European descent populations 81 have made a consistent observation: PRS predict individual risk far more accurately in 82 Europeans than non-Europeans. In complex traits including height, body mass index 83 (BMI), educational attainment, schizophrenia, and major depression, existing PRS computed with the largest available GWAS results predict outcomes far more accurately 84 in new samples of European-descent than they do in non-Europeans, with the clearest 85 study examples in East Asians and African Americans^{15,16,18-24}. Rather than chance or 86 87 biology, this is a predictable consequence of the fact that the genetic discovery efforts to 88 date heavily underrepresent non-European populations globally. The correlation 89 between true and genetically predicted phenotypes decays with genetic divergence 90 from the makeup of the discovery GWAS, meaning that the accuracy of polygenic 91 scores in different populations is highly dependent on the study population

92 representation in the largest existing 'training' GWAS. Here, we document study biases 93 that underrepresent non-European populations in current GWAS, and explain the 94 fundamental concepts contributing to reduced phenotypic variance explained with 95 increasing genetic divergence from populations included in GWAS. 96 97 Predictable basis of disparities in polygenic risk score accuracy 98 Poor generalizability of genetic studies across populations arises from the 99 overwhelming abundance of European descent studies and dearth of well-powered studies in globally diverse populations ²⁵⁻²⁸. According to the GWAS catalog, ~79% of all 100 101 GWAS participants are of European descent despite making up only 16% of the global 102 population (Figure 1). This is especially problematic as previous studies have shown 103 that Hispanic/Latino and African American studies have contributed an outsized number of associations relative to studies of similar sizes in Europeans²⁷. More concerningly, 104 105 the fraction of non-European individuals in GWAS has stagnated or declined since late 106 2014 (Figure 1), suggesting that we are not on a trajectory to correct this imbalance. 107 These numbers provide a composite metric of study availability, accessibility, and use— 108 i.e., cohorts that have been included in numerous GWAS are represented multiple 109 times, which may disproportionately include cohorts of European descent. Whereas the 110 average sample sizes of GWAS in Europeans continue to grow though, they have 111 stagnated and remain several-fold smaller in other populations (Figure S1).

112

113 The relative sample compositions of GWAS result in highly predictable disparities in 114 prediction accuracy; statistical and population genetics theory predicts that genetic risk

115 prediction accuracy will decay with increasing genetic divergence between the original GWAS sample and target of prediction, a function of population history ^{13,14}. This pattern 116 can be attributed to several statistical observations which we detail below: 1) GWAS 117 118 favor the discovery of genetic variants that are common in the study population; 2) linkage disequilibrium (LD) differentiates marginal effect size estimates for highly 119 polygenic traits across populations, even when causal variants are the same; and 3) 120 environment and demography differ across populations, which may interact to drive 121 122 differential forces of natural selection that in turn drive differences in causal genetic architecture. Of note, the first two of these degrade prediction performance across 123 populations substantially even when there exist no biological, environmental, or 124 diagnostic differences. 125

126

127 Common discoveries and low-hanging fruit

First, the power to discover an association in a genetic study depends on the effect size 128 and frequency of the variant ²⁹. This power dependence means that the most significant 129 associations tend to be more common in the populations in which they are discovered 130 than in other populations ^{13,30}. For example, GWAS catalog variants are on average 131 more common in European populations compared to East Asian and African 132 populations (Figure 2B), an observation not representative of genomic variants at large. 133 134 Understudied populations offer low-hanging fruit for genetic discovery because variants 135 that are common in these groups but rare or absent in European populations could not

^{*} We define the causal genetic architecture as the true effects (typically written as β in the GWAS literature) of variants that impact a phenotype that would be identified in a population of infinite sample size. Unlike effect size estimates (usually written as $\hat{\beta}$), true effects are typically modeled as invariant with respect to LD and allele frequency differences across populations.

136 be discovered even with very large European sample sizes. Some examples include 137 SLC16A11 and HNF1A associations with type II diabetes in Latino populations, APOL1 138 associations with end-stage kidney disease, and associations with prostate cancer in African descent populations ³¹⁻³⁴. If we assume that causal genetic variants have an 139 equal effect across all populations-an assumption with some empirical support that 140 offers the best case scenario for transferability ³⁵⁻⁴⁰—Eurocentric GWAS biases mean 141 142 that variants that are common in European populations are preferentially discovered 143 and associated with risk, and thus account for a larger fraction of the variance in polygenic risk ¹³. Furthermore, imputation reference panels share the same study 144 biases as in GWAS⁴¹, creating challenges for imputing sites that are rare in European 145 146 populations but common elsewhere when the catalog of non-European haplotypes is substantially smaller. These issues are insurmountable through statistical methods 147 alone ¹³, but rather motivate substantial investments in more diverse populations to 148 149 produce similar-sized GWAS of biomedical phenotypes as well as sequenced reference 150 panels in other populations.

151

152 Linkage disequilibrium

Second, the correlation structure of the human genome, i.e. LD, varies across populations due to demographic history (**Figure 2A,C-E**). These LD differences in turn drive differences in effect size estimates (i.e. predictors) from GWAS across populations, even when causal effects are the same. (Mathematically, the marginal GWAS estimate $\hat{\beta}_i = \sum_{k=1}^m r_{i,k} \beta_k + \epsilon_i$, where $\hat{\beta}_i$ are effect size estimates at SNP *j*, $r_{i,k}$ is

pairwise SNP LD between SNPs *j* and *k*, β_k is the causal SNP effect at nearby SNP *k*,

159 and ϵ is residual error from bias or noise. More simply, when causal effects are the same 160 across populations, effect size estimates at SNPs tagging these causal variants from which we 161 construct predictors will differ across populations in proportion to LD between tagging and 162 causal SNP pairs.) While differences in effect size estimates due to LD differences may typically be small for most regions of the genome (Figure 2C-E), PRS sum across these 163 effects, also aggregating these population differences. Statistical methods that account 164 165 for LD differences across populations may help improve risk prediction accuracy within 166 each population. While empirical studies suggest that causal effect sizes tend to be shared ³⁵⁻⁴⁰, it may not be feasible to fine-map most variants to a single locus to solve 167 168 issues of low generalizability (i.e. using causal rather than correlated effect size 169 estimates), even with very large GWAS. This is because complex traits are highly 170 polygenic, meaning most of our prediction power comes from small effects that do not 171 meet genome-wide significance and/or cannot be fine-mapped, even in many of the best-powered GWAS to date ⁴². 172

173

174 History, selection, the environment, and complex interactions

175 Lastly, other environmental, demographic, and cohort considerations may further 176 worsen prediction accuracy differences across populations in less predictable ways. 177 GWAS ancestry study biases and LD differences across populations are extremely 178 challenging to address, but these issues actually make many favorable assumptions 179 that all causal loci have the same impact and are under equivalent selective pressure in 180 all populations. In contrast, other effects on polygenic adaptation or risk scores such as 181 long-standing environmental differences across global populations that have resulted in 182 differing responses of natural selection can impact populations differently based on their 183 unique histories. Additionally, residual uncorrected population stratification may impact 184 risk prediction accuracy across populations, but the magnitude of its effect is currently 185 unclear. These effects are particularly challenging to disentangle, as has clearly been 186 demonstrated for height, where evidence of polygenic adaptation and/or its relative magnitude is under question ^{43,44}. Comparisons of geographically stratified phenotypes 187 188 like height across populations with highly divergent genetic backgrounds and mean 189 environmental differences, such as differences in resource abundance during 190 development across continents, are especially prone to confounding from correlated environmental and genetic divergence ^{43,44}. This residual stratification can lead to over-191 predicted differences across geographical space ⁴⁵. 192 193

194 Related to stratification, most polygenic scoring methods do not explicitly address 195 recent admixture and none consider recently admixed individuals' unique local mosaic 196 of ancestry—further methods development in this space is needed. Furthermore, 197 comparing PRS across environmentally stratified cohorts, such as in some biobanks 198 with healthy volunteer effects versus disease study datasets or hospital-based cohorts, requires careful consideration of technical differences, collider bias, as well as variability 199 200 in baseline health status among studies. It is also important to consider differences in 201 clinical definition of the phenotypes and heterogeneous constitution of sub-phenotypes 202 among countries.

203

Another consideration is the fact that, like other existing biomarkers, the predictive utility of PRS may change as a function of age, consistent with age-dependent heritability for

some traits ⁴⁶. For example, increasing age is associated with higher risk of coronary 206 artery disease, and higher PRS accelerate this increased risk ⁴⁷. Consequently, the age 207 208 of intervention e.g. with stating needs to be evaluated in aggregate with other clinical 209 risk factors that change over time. Autism spectrum disorder and schizophrenia also 210 have a genetic basis with differing developmental trajectories; their shared genetic influences decrease with age, whereas the genetic overlap between schizophrenia and 211 social communication difficulties persists with age ⁴⁸. Further work on how prediction 212 213 accuracy varies as a function of age across phenotypes is needed.

214

Differences in environmental exposure, gene × gene interactions, gene × environment 215 216 interactions, historical population size dynamics, and other factors will further limit generalizability for genetic risk scores in an unpredictable, trait-specific fashion ^{49,50}. 217 218 Complex traits do not behave in a genetically deterministic manner, with some 219 environmental factors dwarfing individual genetic effects, creating outsized issues of 220 comparability across globally diverse populations; among psychiatric disorders for 221 example, whereas schizophrenia has a nearly identical genetic basis across East Asians and Europeans (r_g =0.98) ⁴⁰, substantially different rates of alcohol use disorder 222 223 across populations is partially explained by differences in availability and genetic differences impacting alcohol metabolism ⁵¹. While non-linear genetic factors explain 224 little variation in complex traits beyond a purely additive model ⁵², some unrecognized 225 226 nonlinearities and gene x gene interactions can also induce genetic risk prediction 227 challenges, as pairwise interactions are likely to vary more across populations than 228 individual SNPs. Mathematically, we can simplistically think of this in terms of a two-

SNP model, in which the sum of two SNP effects is likely to explain more phenotypic
 variance than the product of the same SNPs. Some machine learning approaches may
 thus modestly improve genetic prediction accuracy beyond current approaches for
 some phenotypes ⁵³, but these approaches are most likely to improve prediction
 accuracy for atypical traits with simpler architectures, known interactions, and poor
 prediction generalizability across populations, such as skin pigmentation ⁵⁴.

235

236 Limited generalizability of genetic prediction across diverse populations

237 Previous work has assessed prediction accuracy across diverse populations in several 238 traits and diseases for which GWAS summary statistics are available. These 239 assessments are becoming increasingly feasible with the growth and public availability 240 of global biobanks for quantitative traits as well as diversifying priorities from funding agencies ^{55,56}. As of yet, multi-ethnic work has been slow in most disease areas ⁵⁷, 241 242 limiting even the opportunity to assess prediction utility in non-European cohorts. 243 Nonetheless, we have assembled prediction accuracy statistics from several studies 244 using the largest European GWAS to predict several phenotypes in target European 245 and non-European cohorts. For example, multiple schizophrenia studies consistently 246 predicted risk on average 2.2-fold worse in East Asians relative to Europeans, (i.e. μ =0.46, σ =0.06), using summary statistics from a Eurocentric GWAS ^{15,18} (**Figure S2**). 247 248 despite the fact that there is no significant genetic heterogeneity in schizophrenia between the two populations ⁴⁰. This finding is even more pronounced in African 249 250 Americans, consistent with higher genetic divergence from Europeans than between Europeans and East Asians³⁰. Across several phenotypes with a range of genetic 251

252 architectures in which empirical evaluations were available, including BMI, educational 253 attainment, height, and schizophrenia, prediction accuracy using European GWAS 254 summary statistics was on average 4.5-fold less accurate in African Americans than in Europeans (i.e. μ =0.22, σ =0.09, **Figure S2**) ^{15,16,19-22}. By extension, prediction accuracy 255 256 is expected to be even lower in African Americans with higher than average African 257 ancestry or among populations with greater divergence from Europeans (e.g. some 258 southern African populations). These enormous disparities are not simply 259 methodological issues, as various approaches (e.g. pruning and threshold versus LDPred) and accuracy metrics (R² for quantitative traits and various pseudo-R² metrics 260 261 for binary traits) illustrate this consistently poorer performance in populations distinct 262 from the discovery sample across a range of polygenic traits (Table S4). We assessed 263 how prediction accuracy decayed across globally diverse populations for 17 264 anthropometric and blood panel traits in the UK Biobank (UKBB) when using European-265 derived summary statistics (Methods); consistent with previous studies, we find that 266 relative to European prediction accuracy, genetic prediction accuracy was far lower in 267 other populations (Figure 3, notably 1.6-fold lower in Hispanic/Latino Americans, 1.7-268 fold lower in South Asians, 2.5-fold lower in East Asians, and 4.9-fold lower in Africans 269 on average).

270

271 Prioritizing diversity shows early promise for polygenic prediction

Early diversifying GWAS efforts have been especially productive for informing on these
questions surrounding risk prediction. Rather than varying the prediction target dataset,
some GWAS in diverse populations have increased the scale of non-European

275	summary statistics and also varied the study dataset in multi-ethnic PRS studies. For
276	example, a BioBank Japan (BBJ) GWAS study (N=158,284) showed that compared to a
277	$2 \times$ larger European GWAS (N=322,154), the variance in BMI explained in an
278	independent Japanese cohort with Japanese GWAS summary statistics was on
279	average 1.5-fold greater than with European GWAS summary statistics (R^2 =0.154 vs
280	0.104 at p < 0.05, respectively) 23 . Relatedly, an East Asian schizophrenia study
281	(N=22,778 cases and 35,362 controls) showed that compared to an effectively $3 \times$ larger
282	European study, prediction accuracy in East Asians was on average 1.3-fold higher
283	than with European summary statistics (liability R^2 =0.029 vs 0.022, respectively) ⁴⁰ .
284	Thus, even when studies in non-European populations are only a fraction the size of the
285	largest European study, they are likely to have disproportionate value for predicting
286	polygenic traits in other individuals of similar ancestry.
287	

288 Given this background, we performed a systematic evaluation of polygenic prediction 289 accuracy across 17 quantitative anthropometric and blood panel traits and five disease endpoints in British and Japanese individuals ^{23,58,59} by performing GWAS with the exact 290 291 same sample sizes in each population. We symmetrically demonstrate that prediction 292 accuracy is consistently higher with GWAS summary statistics from ancestry-matched 293 summary statistics (Figure 4, Figure S8–12). Keeping in mind issues of comparability 294 described above, we note that BBJ is a hospital-based disease-ascertained cohort, 295 whereas UKBB is a healthier than average population-based cohort; thus, differences in 296 observed heritability among these cohorts (rather than among populations) due to 297 differences in phenotype precision likely explain lower prediction accuracy from the BBJ

298 GWAS summary statistics for anthropometric and blood panel traits, but higher 299 prediction accuracy for five ascertained diseases (Table S5). Indeed, other East Asian 300 studies have estimated higher heritability for some quantitative traits than BBJ using the same methods, such as for height ($h^2 = 0.48 \pm 0.04$ in Chinese women) ⁶⁰. Some 301 302 statistical fluctuations in the relative differences in prediction accuracy across 303 populations are likely driven by differences in heritability measured in each population 304 and/or trans-ethnic genetic correlation[†] (Figure S4-7, Table S5–8). These correlation 305 estimates indicate that effect sizes were mostly highly correlated across ancestries, with 306 a few traits that were somewhat lower than excepted (e.g. height and BMI, with $\rho_{\rm re}$ =0.69 and 0.75, respectively); effect sizes can be different across populations due to 307 308 natural selection differences, gene-gene interactions, gene-environment interactions, statistical noise, and/or other phenomena ⁶¹. Prediction accuracy was far lower in 309 310 individuals of African descent in the UK Biobank (Figure S10 and S13) using GWAS 311 summary statistics from either European or Japanese ancestry individuals, consistent 312 with reduced prediction accuracy with increasing genetic divergence (Figures 3 and 4). 313 These population studies demonstrate the power and utility of increasingly diverse GWAS for prediction, especially in populations of non-European descent. 314 315 316 While many other traits and diseases have been studied in multi-ethnic settings, few 317 have reported comparable metrics of prediction accuracy across populations.

- 318 Cardiovascular research, for example, has led the charge towards clinical translation of
- ³¹⁹ PRS¹. This enthusiasm is driven by observations that a polygenic burden of LDL-

[†] Trans-ethnic genetic correlation compares the estimated correlation of common variant effect sizes at SNPs common in two populations, here using Popcorn ⁶¹.

increasing SNPs can confer monogenic-equivalent risk of cardiovascular disease, with 320 321 polygenic scores improving clinical models for risk assessment and statin prescription 322 that can reduce coronary heart disease and improve healthcare delivery efficiency ^{5,6,8}. 323 However, many of these studies have been conducted exclusively in European descent 324 populations, with few studies rigorously evaluating population-level applicability to non-325 Europeans. Those existing findings indeed demonstrate a large reduction in prediction 326 utility in non-European populations¹¹, though often with comparisons of odds ratios 327 among arbitrary breakpoints in the risk distribution that make comparisons across 328 studies challenging. To better clarify how polygenic prediction will be deployed in a 329 clinical setting with diverse populations, more systematic and thorough evaluations of 330 the utility of PRS within and across populations for many complex traits are still needed. 331 These evaluations would benefit from rigorous polygenic prediction accuracy evaluations, especially for diverse non-European patients ⁶²⁻⁶⁴. 332

333

334 Translational genetic prediction may uniquely exacerbate disparities

335 Our impetus for raising these statistical issues limiting the generalizability of PRS across 336 population stems from our concern that, while they are legitimately clinically promising 337 for improving health outcomes for many biomedical phenotypes, they may have a larger 338 potential to raise health disparities than other clinical factors for several reasons. The 339 opportunities they provide for improving health outcomes means they inevitably will and 340 should be pursued in the near term, but we urge that a concerted prioritization to make 341 GWAS summary statistics easily accessible for diverse populations and a variety of 342 traits and diseases is imperative, even when they are a fraction the size of the largest

existing European datasets. Individual clinical tests, biomarkers, and prescription drug 343 344 efficacy may vary across populations in their utility, but are fundamentally informed by the same underlying biology ^{65,66}. Currently, guidelines state that as few as 120 345 346 individuals define reference intervals for clinical factors (though often smaller numbers 347 from only one subpopulation are used) and there is no clear definition of who is "normal" ⁶⁵. Consequently, reference intervals for biomarkers can sometimes deviate 348 considerably by reported ethnicity⁶⁷⁻⁶⁹. Defining ethnicity-specific reference intervals is 349 350 clearly an important problem that can provide fundamental interpretability gains with 351 implications for some major health benefits (e.g. need for dialysis and development of Type 2 diabetes based on ethnicity-specific serum creatinine and hemoglobin A1C 352 reference intervals, respectively) ⁶⁸. Simply put, some biomarkers or clinical tests scale 353 354 directly with health outcomes independent of ancestry, and many others may have 355 distributional differences by ancestry but are equally valid after centering with respect to 356 a readily collected population reference.

357

In contrast, PRS are uniformly less useful in understudied populations due to
differences in genomic variation and population history ^{13,14}. No analogous solution of
defining ethnicity-specific reference intervals would ameliorate health disparities
implications for PRS or fundamentally aid interpretability in non-European populations.
Rather, as we and others demonstrate, PRS are unique in that even with multi-ethnic
population references, these scores are fundamentally less informative in populations
more diverged from GWAS study cohorts.

365

366 The clinical use and deployment of genetic risk scores needs to be informed by the 367 issues surrounding tests that currently would unequivocally provide much greater 368 benefit to the subset of the world's population which is already on the positive end of healthcare disparities[‡]. Conversely, African descent populations, which already endure 369 370 many of the largest health disparities globally, are often predicted marginally better, if at 371 all, compared to random (Figure 4F). They are therefore least likely to benefit from 372 improvements in precision healthcare delivery from genetic risk scores with existing 373 data due to human population history and study biases. This is a major concern globally 374 and especially in the U.S., which already leads other middle- and high-income countries in both real and perceived healthcare disparities ⁷⁰. Thus, we would strongly urge that 375 376 any discourse on clinical use of polygenic scores include a careful, quantitative 377 assessment of the economic and health disparities impacts on underrepresented 378 populations that might be unintentionally introduced by the use of PRS and raise 379 awareness about how to eliminate these disparities.

380

381 How do we even the ledger?

What can be done? The single most important step towards parity in PRS accuracy in diverse populations is by vastly increasing the diversity of participants included and analyzed in genetic studies. Regulatory protections against genetic discrimination are necessary to accompany calls for more diverse studies; while some already exist in the U.S., including for health insurance and employment opportunities via the Genetic Information Nondiscrimination Act (GINA), stronger protections in these and other areas

[‡] To maximally benefit all populations, the largest existing GWAS results should be used. Downsampling European GWAS for the sake of parity results in worse predictors for all individuals.

388 globally will be particularly important for minorities and/or marginalized groups. An equal 389 investment in GWAS across all major ancestries and global populations is the most 390 obvious solution to generate a substrate for equally informative risk scores but is not 391 likely to occur any time soon absent a dramatic priority shift given the current imbalance and stalled diversifying progress over the last five years (Figure 1, Figure S1). While it 392 393 may be challenging or in some cases infeasible to acquire sample sizes large enough 394 for PRS to be equally informative in all populations, some much-needed efforts towards 395 increasing diversity in genomics that support open sharing of GWAS summary data 396 from multiple ancestries are underway. Examples include the All of Us Research 397 Program, the Population Architecture using Genomics and Epidemiology (PAGE) 398 Consortium, as well as some disease-focused consortia, such as the T2D-genes and 399 Stanley Global initiatives on the genetics of type II diabetes and psychiatric disorders. respectively[§]. Supporting data resources such as imputation panels, multi-ethnic 400 genotyping arrays, gene expression datasets from genetically diverse individuals, and 401 402 other tools are necessary to similarly empower these diverse studies to most effectively improve predictive accuracy for all populations. The lack of supporting resources for 403 404 diverse ancestries creates financial challenges for association studies with limited 405 resources, e.g. raising questions about whether to genotype samples on GWAS arrays 406 that may favor European allele frequencies versus sequence samples, and how dense of an array to choose or how deeply to sequence 71,72 . 407

[§] For these diverse studies in the U.S. and globally, genetically determined ancestry and populations are important to delineate from self-identified race/ethnicity, as only controlling for the former can account for stratification of allele frequencies within a population.

409 Additional leading global efforts also provide easy unified access linking genetic, clinical 410 record, and national registry data in more homogeneous continental ancestries, such as 411 the UK Biobank, BioBank Japan, China Kadoorie Biobank, and Nordic efforts (e.g. in 412 Danish, Estonian, Finnish, and other integrated biobanks). Notably, some of these 413 biobanks such as UK Biobank have participants with considerable global genetic 414 diversity that enables multi-ethnic comparisons; although minorities from this cohort 415 provide the largest deeply phenotyped GWAS cohorts for several ancestries, these 416 individuals are often excluded in current statistical analyses in favor of single ancestries, 417 large sample sizes, and the simplicity afforded by genetic homogeneity. These 418 considerations notwithstanding, there are critical needs and challenges for expanding 419 the scale of genetic studies of heritable traits in diverse populations; this is especially 420 apparent in Africa where humans originated and retain the most genetic diversity, as 421 Africans are understudied but disproportionately informative for genetic analyses and evolutionary history ^{27,73}. The most notable investment here comes from the Human 422 423 Heredity and Health in Africa (H3Africa) Initiative, increasing genomics research 424 capacity in Africa through more than \$216 million in funding from the NIH (USA) and Wellcome Trust (UK) for genetics research led by African investigators ^{56,74}. The 425 426 increasing interest and scale of genetic studies in low- and middle-income countries 427 (LMICs) raises ethical and logistical considerations about data generation, access, 428 sharing, security, and analysis, as well as clinical implementation to ensure these 429 advances do not only benefit high-income countries. Frameworks such as the H3ABioNet, a pan-African bioinformatics network designed to build capacity to enable 430

H3Africa researchers to analyze their data in Africa, provide cost-effective examples for
 training local scientists in LMICs ⁷⁵.

433

434 The prerequisite data for dramatically increasing diversity also hypothetically exist in 435 several large-scale publicly funded datasets such as the Million Veterans Project and 436 Trans-Omics for Precision Medicine (TOPMed), but with problematic data access issues 437 in which even summary data from GWAS within and across populations are not publicly 438 shared. Existing GWAS consortia also need to carefully consider the granularity of 439 summary statistics they release, as finer scale continental ancestries and phenotypes in 440 large, multi-ethnic projects enable ancestry-matched analyses not possible with a single 441 set of summary statistics. While there is an understandable patient privacy balance to 442 strike when sharing individual-level data, GWAS summary statistics from all publicly 443 funded and as many privately funded projects as possible should be made easily and 444 publicly accessible to improve global health outcomes. Efforts to unify phenotype 445 definitions, normalization approaches, and GWAS methods among studies will also improve comparability. 446

447

To enable progress towards parity, it will be critical that open data sharing standards be adopted for all ancestries and for genetic studies of all sample sizes, not just the largest European results. Locally appropriate and secure genetic data sharing techniques as well as equitable technology availability will need to be adopted widely in Asia and Africa as they are in Europe and North America, to ensure that maximum value is achieved from existing and ongoing efforts that are being developed to help counter the

454 current imbalance. Simultaneously, ethical considerations require that research capacity 455 is increased in LMICs with simultaneous growth of diverse population studies to balance 456 the benefits of these studies to scientists and patients globally versus locally to ensure 457 that everyone benefits. Methodological improvements that better define risk scores by 458 accounting for population allele frequency, LD, and/or admixture differences 459 appropriately are underway and may help considerably but will not by themselves bring 460 equality. All of these efforts are important and should be prioritized not just for risk 461 prediction but more generally to maximize the use and applicability of genetics to inform 462 on the biology of disease. Given the acute recent attention on clinical use of PRS, we 463 believe it is paramount to recognize their potential to improve health outcomes for all 464 individuals and many complex diseases. Simultaneously, we as a field must address the 465 disparity in utility in an ethically thoughtful and scientifically rigorous fashion, lest we 466 inadvertently enable genetic technologies to contribute to, rather than reduce, existing 467 health disparities.


468

469 Acknowledgments

We thank Amit Khera for helpful discussions. We also thank Michiaki Kubo, Yoshinori
Murakami, Masato Akiyama, and Kazuyoshi Ishigaki for their support in the BioBank
Japan Project analysis. We are grateful to Steven Gazal for his help in calculating LD
scores. This work was supported by funding from the National Institutes of Health
(K99MH117229 to A.R.M.). UK Biobank analyses were conducted via application
31063. The BioBank Japan Project was supported by the Tailor-Made Medical
Treatment Program of the Ministry of Education, Culture, Sports, Science, and

bioRxiv preprint doi: https://doi.org/10.1101/441261; this version posted January 3, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

- 477 Technology (MEXT) and the Japan Agency for Medical Research and Development
- 478 (AMED). M.K. was supported by a Nakajima Foundation Fellowship and the Masason
- 479 Foundation.
- 480
- 481 Figures






483 Figure 1 – Ancestry of GWAS participants over time compared to the global

484 **population**. Cumulative data as reported by the GWAS catalog ²⁷. A notable caveat is

that because some cohorts are included in numerous studies, some individuals are

- represented multiple times. This bias in multiple counting is especially likely for publicly
- 487 available cohorts, which are more likely to be of European or East Asian descent.
- 488 Individuals whose ancestry is "not reported" are not shown.


bioRxiv preprint doi: https://doi.org/10.1101/441261; this version posted January 3, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.



489

Figure 2 – Demographic relationships, allele frequency differences, and local LD 490 491 patterns between population pairs. Data analyzed from 1000 Genomes, in which 492 population labels are: AFR = continental African, EUR = European, and EAS = East 493 Asian. A) Cartoon relationships among AFR, EUR, and EAS populations. B) Allele 494 frequency distributions in AFR, EUR, and EAS populations of variants from the GWAS catalog. C-E) Color axis shows LD scale (r^2) . LD comparisons between pairs of 495 496 populations show the same region of the genome for each comparison (representative 497 region is chr1, 51572kb-52857kb) among pairs of SNPs polymorphic in both 498 populations, illustrating that different SNPs are polymorphic across some population 499 pairs, and that these SNPs have variable LD patterns across populations. 500

bioRxiv preprint doi: https://doi.org/10.1101/441261; this version posted January 3, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



502 **Figure 3 – Prediction accuracy relative to European ancestry individuals across**

503 **17 quantitative traits and 5 continental populations in UKBB**. All phenotypes shown

here are quantitative anthropometric and blood panel traits, as described in **Table S1**,

- 505 including sample sizes. Bars show mean values, and error bars show standard errors of
- 506 the means.
- 507

bioRxiv preprint doi: https://doi.org/10.1101/441261; this version posted January 3, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.




Figure 4 – Polygenic risk prediction accuracy in Japanese, British, and African 509 510 descent individuals using independent GWAS of equal sample sizes in the 511 BioBank Japan and UK Biobank. All target prediction cohorts are withheld from the GWAS and thus independent. Sample sizes in each GWAS are identical by design 512 513 between BBJ and UKBB (Table S1 and S3). To optimize signal to noise, each point shows the maximum R^2 (i.e. best predictor) across five p-value thresholds. R^2 values for 514 all p-value thresholds are shown in Figures S8-S12. Prediction accuracy tends to be 515 516 higher in the UK Biobank for quantitative traits than in BioBank Japan and vice versa for 517 disease endpoints, likely because of concomitant phenotype precision and

consequently observed heritability for these classes of traits (Table S5-S7)**. 518 519 Abbreviations are as follows: AFib = atrial fibrillation, BMI = body mass index, CRC = 520 colorectal cancer, DBP = diastolic blood pressure, Hb = hemoglobin, Ht = Hematocrit, 521 MCH = mean corpuscular hemoglobin, MCHC = mean corpuscular hemoglobin 522 concentration, MCV = mean corpuscular volume, RA = rheumatoid arthritis, RBC = red 523 blood cell count, SBP = systolic blood pressure, T2D = type 2 diabetes, WBC = white 524 blood cell count. A) Explanatory diagram showing the different discovery and target 525 cohorts/populations, and quantitative traits versus disease endpoints. B) Genetic 526 prediction accuracy for five diseases in Japanese individuals using summary statistics 527 from GWAS of independent BioBank Japan versus UK Biobank samples. C) Genetic 528 prediction accuracy for the same five diseases in independent British individuals using 529 summary statistics from GWAS of independent BioBank Japan versus the UK Biobank 530 samples. D) Genetic prediction accuracy for 17 anthropometric and blood panel traits in 531 Japanese individuals using summary statistics from GWAS of independent BioBank 532 Japan versus UK Biobank samples. E) Genetic prediction accuracy for the same 17 533 anthropometric and blood panel traits in independent British individuals using summary 534 statistics from GWAS of independent BioBank Japan versus the UK Biobank samples. 535 F) Genetic prediction accuracy for 17 anthropometric and blood panel traits in African descent individuals in the UK Biobank using summary statistics from GWAS of 536 537 independent BioBank Japan versus UK Biobank samples.

^{**} Thalassemia and sickle cell disease are unlikely to explain a significant fraction of these prediction differences, as few individuals have been diagnosed with these disorders via ICD-10 codes (**Table S11**).

538 References

- Knowles, J. W. & Ashley, E. A. Cardiovascular disease: The rise of the genetic
 risk score. *PLoS Med* 15, e1002546–7 (2018).
- Maas, P. *et al.* Breast Cancer Risk From Modifiable and Nonmodifiable Risk
 Factors Among White Women in the United States. *JAMA Oncol* 2, 1295–8
 (2016).
- Mavaddat, N. *et al.* Polygenic Risk Scores for Prediction of Breast Cancer and
 Breast Cancer Subtypes. *The American Journal of Human Genetics* 1–42 (2018).
 doi:10.1016/j.ajhg.2018.11.002
- 547 4. Schumacher, F. R. *et al.* Association analyses of more than 140,000 men identify
 548 63 new prostate cancer susceptibility loci. *Nat Genet* 1–13 (2018).
 549 doi:10.1038/s41588-018-0142-8
- 550 5. Khera, A. V. *et al.* Genome-wide polygenic score to identify a monogenic riskequivalent for coronary disease. (2017). doi:10.1101/218388
- Kullo, I. J. *et al.* Incorporating a Genetic Risk Score Into Coronary Heart Disease
 Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MIGENES Clinical Trial). *Circulation* **133**, 1181–1188 (2016).
- 555 7. Paquette, M. *et al.* Polygenic risk score predicts prevalence of cardiovascular
 556 disease in patients with familial hypercholesterolemia. *Journal of Clinical*557 *Lipidology* 11, 725–732.e5 (2017).
- Natarajan, P. *et al.* Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention SettingClinical Perspective. *Circulation* 135, 2091–2101 (2017).
- 562 9. Tikkanen, E., Havulinna, A. S., Palotie, A., Salomaa, V. & Ripatti, S. Genetic risk
 563 prediction and a 2-stage risk screening strategy for coronary heart disease.
 564 *Arterioscler. Thromb. Vasc. Biol.* 33, 2261–2266 (2013).
- Frieser, M. J., Wilson, S. & Vrieze, S. Behavioral Impact of Return of Genetic Test
 Results for Complex Disease: Systematic Review and Meta-Analysis. *Health Psychol* 37, 1134–1144 (2018).
- 568 11. Khera, A. V. *et al.* Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary
 569 Disease. *N Engl J Med* **375**, 2349–2358 (2016).
- 570 12. Khera, A. V. & Kathiresan, S. Genetics of coronary artery disease: discovery, 571 biology and clinical translation. *Nat Rev Genet* **18**, 331–344 (2017).
- 57213.Martin, A. R. *et al.* Human Demographic History Impacts Genetic Risk Prediction573across Diverse Populations. *Am. J. Hum. Genet.* **100**, 635–649 (2017).
- Scutari, M., Mackay, I. & Balding, D. Using Genetic Distance to Infer the Accuracy
 of Genomic Prediction. *PLoS Genet* 12, e1006288 (2016).
- Vilhjálmsson, B. J. *et al.* Modeling Linkage Disequilibrium Increases Accuracy of
 Polygenic Risk Scores. *The American Journal of Human Genetics* 97, 576–592
 (2015).
- 16. Ware, E. B. *et al.* Heterogeneity in polygenic scores for common human traits. 1– 13 (2017). doi:10.1101/106062

581 17. Curtis, D. Polygenic risk score for schizophrenia is more strongly associated with 582 ancestry than with schizophrenia. *bioRxiv* (2018). 583 doi:https://doi.org/10.1101/287136 584 18. Ripke, S. et al. Biological insights from 108 schizophrenia-associated genetic loci. 585 Nature 511, 421–427 (2014). 586 19. Belsky, D. W. et al. Development and Evaluation of a Genetic Risk Score for 587 Obesity. Biodemography and Social Biology 59, 85–100 (2013). 588 20. Domingue, B. W., Belsky, D. W., Conley, D., Harris, K. M. & Boardman, J. D. 589 Polygenic Influence on Educational Attainment. AERA Open 1, 590 233285841559997-13 (2015). 591 21. Wedow, R. et al. Gene discovery and polygenic prediction from a genome-wide 592 association study of educational attainment in 1.1 million individuals. Nat Genet 593 **92,** 109 (2018). 594 22. Vassos, E. et al. An Examination of Polygenic Score Risk Prediction in Individuals 595 With First-Episode Psychosis. *Biological Psychiatry* **81**, 470–477 (2017). 596 23. Akiyama, M. et al. Genome-wide association study identifies 112 new loci for 597 body mass index in the Japanese population. Nat Genet 49, 1458–1467 (2017). 598 24. Li, Z. et al. Genome-wide association analysis identifies 30 new susceptibility loci 599 for schizophrenia. Nature Publishing Group 49, 1576–1583 (2017). 600 25. Need, A. C. & Goldstein, D. B. Next generation disparities in human genomics: 601 concerns and remedies. Trends in Genetics 25, 489-494 (2009). 602 Popejoy, A. B. & Fullerton, S. M. Genomics is failing on diversity. Nature 538, 26. 603 161–164 (2016). Morales, J. et al. A standardized framework for representation of ancestry data in 604 27. 605 genomics studies, with application to the NHGRI-EBI GWAS Catalog. 1–10 606 (2018). doi:10.1186/s13059-018-1396-2 607 28. Rosenberg, N. A. et al. Genome-wide association studies in diverse populations. 608 Nat Rev Genet 11, 356–366 (2010). 609 29. Sham, P. C., Cherny, S. S., Purcell, S. & Hewitt, J. K. Power of linkage versus 610 association analysis of quantitative traits, by use of variance-components models, for sibship data. The American Journal of Human Genetics 66, 1616–1630 611 612 (2000).613 1000 Genomes Project Consortium et al. A global reference for human genetic 30. 614 variation. Nature 526, 68-74 (2015). 615 31. Consortium, T. S. 2. D. Sequence variants in SLC16A11 are a common risk factor 616 for type 2 diabetes in Mexico. Nature 506, 97-101 (2014). Estrada, K. et al. Association of a Low-Frequency Variant in HNF1A With Type 2 617 32. 618 Diabetes in a Latino Population. JAMA 311, 2305–2314 (2014). 619 33. Haiman, C. A. et al. Genome-wide association study of prostate cancer in men of 620 African ancestry identifies a susceptibility locus at 17g21. Nat Genet 43, 570-573 621 (2011). 622 Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney 34. 623 disease in African Americans. Science 329, 841-845 (2010). 624 35. Liu, J. Z. et al. Association analyses identify 38 susceptibility loci for inflammatory 625 bowel disease and highlight shared genetic risk across populations. Nat Genet **47.** 979–986 (2015). 626

<u> </u>	00	
627	36.	Carlson, C. S. <i>et al.</i> Generalization and Dilution of Association Results from
628		European GWAS in Populations of Non-European Ancestry: The PAGE Study.
629	07	<i>PLoS Biol</i> 11 , e1001661 (2013).
630	37.	Easton, D. F. <i>et al.</i> Genome-wide association study identifies novel breast cancer
631	20	susceptibility loci. <i>Nature</i> 447 , 1087–1093 (2007).
632	38.	Mahajan, A. et al. Genome-wide trans-ancestry meta-analysis provides insight
633		into the genetic architecture of type 2 diabetes susceptibility. Nat Genet 46, 234-
634	~~	244 (2014).
635	39.	Waters, K. M. et al. Consistent Association of Type 2 Diabetes Risk Variants
636		Found in Europeans in Diverse Racial and Ethnic Groups. <i>PLoS Genet</i> 6,
637		e1001078 (2010).
638	40.	Lam, M. et al. Comparative genetic architectures of schizophrenia in East Asian
639		and European populations. 1–41 (2018). doi:10.1101/445874
640	41.	McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype
641		imputation. Nat Genet 48, 1279–1283 (2016).
642	42.	Huang, H. et al. Fine-mapping inflammatory bowel disease loci to single-variant
643		resolution. <i>Nature</i> 547, 173–178 (2017).
644	43.	Berg, J. J. et al. Reduced signal for polygenic adaptation of height in UK Biobank.
645		1–44 (2018). doi:10.1101/354951
646	44.	Sohail, M. et al. Signals of polygenic adaptation on height have been
647		overestimated due to uncorrected population structure in genome-wide
648		association studies. 1–44 (2018). doi:10.1101/355057
649	45.	Kerminen, S. et al. Geographic variation and bias in polygenic scores of complex
650		diseases and traits in Finland:. (2018). doi:10.1101/485441
651	46.	Ge, T., Chen, CY., Neale, B. M., Sabuncu, M. R. & Smoller, J. W. Phenome-
652		wide heritability analysis of the UK Biobank. PLoS Genet 13, e1006711–21
653		(2017).
654	47.	Inouye, M. et al. Genomic Risk Prediction of Coronary Artery Disease in 480,000
655		Adults: Implications for Primary Prevention. J. Am. Coll. Cardiol. 72, 1883–1893
656		(2018).
657	48.	Pourcain, B. S. et al. ASD and schizophrenia show distinct developmental profiles
658		in common genetic overlap with population-based social communication
659		difficulties. Molecular Psychiatry 1–8 (2016). doi:10.1038/mp.2016.198
660	49.	Novembre, J. & Barton, N. H. Tread Lightly Interpreting Polygenic Tests of
661		Selection. Genetics 208, 1351–1355 (2018).
662	50.	Henn, B. M., Botigué, L. R., Bustamante, C. D., Clark, A. G. & Gravel, S.
663		Estimating the mutation load in human genomes. Nat Rev Genet 16, 333–343
664		(2015).
665	51.	Li, D., Zhao, H. & Gelernter, J. Strong protective effect of the aldehyde
666		dehydrogenase gene (ALDH2) 504lys (*2) allele against alcoholism and alcohol-
667		induced medical diseases in Asians. Human Genetics 131, 725–737 (2011).
668	52.	Zhu, Z. et al. Dominance Genetic Variation Contributes Little to the Missing
669		Heritability for Human Complex Traits. The American Journal of Human Genetics
670		96, 377–385 (2015).
671	53.	Paré, G., Mao, S. & Deng, W. Q. A machine-learning heuristic to improve gene
672		score prediction of polygenic traits. Sci Rep 7, 12665 (2017).

673	54.	Martin, A. R. et al. An Unexpectedly Complex Architecture for Skin Pigmentation
674		in Africans. (2017). doi:10.1101/200139
675	55.	Hindorff, L. A. et al. Prioritizing diversity in human genomics research. Nature
676		Publishing Group 1–11 (2017). doi:10.1038/nrg.2017.89
677	56.	H3Africa Consortium et al. Research capacity. Enabling the genomic revolution in
678		Africa. Science 344 , 1346–1348 (2014).
679	57.	Duncan, L. E. <i>et al.</i> Largest GWAS of PTSD (N=20 070) yields genetic overlap
680		with schizophrenia and sex differences in heritability. <i>Molecular Psychiatry</i> (2017).
681		doi:10.1038/mp.2017.77
682	58.	Howrigan, D. Details and Considerations of the Uk Biobank GWAS.
683		http://www.nealelab.is/blog/2017/9/11/details-and-considerations-of-the-uk-
684		biobank-gwas (2017). Available at: (Accessed: 9 November 2017)
685	59.	Kanai, M. et al. Genetic analysis of quantitative traits in the Japanese population
686		links cell types to complex human diseases. Nat Genet 1–16 (2018).
687		doi:10.1038/s41588-018-0047-6
688	60.	Liu, S. et al. Genomic Analyses from Non-invasive Prenatal Testing Reveal
689		Genetic Associations, Patterns of Viral Infections, and Chinese Population
690		History. Cell 175, 347–359.e14 (2018).
691	61.	Brown, B. C., Ye, C. J., Price, A. L. & Zaitlen, N. Transethnic Genetic-Correlation
692		Estimates from Summary Statistics. The American Journal of Human Genetics
693		99, 76–88 (2016).
694	62.	Wray, N. R. et al. Pitfalls of predicting complex traits from SNPs. Nature
695	-	Publishing Group 14, 507–515 (2013).
696	63.	Wray, N. R. et al. Research Review: Polygenic methods and their application to
697		psychiatric traits. J Child Psychol Psychiatr 55, 1068–1087 (2014).
698	64.	Torkamani, A., Wineinger, N. E. & Topol, E. J. The personal and clinical utility of
699	• • •	polygenic risk scores. <i>Nat Rev Genet</i> 1–10 (2018). doi:10.1038/s41576-018-
700		0018-x
701	65.	Manrai, A. K., Patel, C. J. & Ioannidis, J. P. A. In the Era of Precision Medicine
702		and Big Data, Who Is Normal? JAMA 319, 1981–1982 (2018).
703	66.	Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets
704		through human genetics. <i>Nature Publishing Group</i> 12 , 581–594 (2013).
705	67.	Carroll, M. D., Kit, B. K., Lacher, D. A., Shero, S. T. & Mussolino, M. E. Trends in
706	••••	lipids and lipoproteins in US adults, 1988-2010. JAMA 308, 1545–1554 (2012).
707	68.	Rappoport, N. <i>et al.</i> Creating ethnicity-specific reference intervals for lab tests
708		from EHR data. <i>bioRxiv</i> (2017). doi:10.1101/213892
709	69.	Lim, E., Miyamura, J. & Chen, J. J. Racial/Ethnic-Specific Reference Intervals for
710		Common Laboratory Tests: A Comparison among Asians, Blacks, Hispanics, and
711		White. Hawaii J Med Public Health 74 , 302–310 (2015).
712	70.	Hero, J. O., Zaslavsky, A. M. & Blendon, R. J. The United States Leads Other
713	. 0.	Nations In Differences By Income In Perceptions Of Health And Health Care.
714		Health Aff 36 , 1032–1040 (2017).
715	71.	Gilly, A. <i>et al.</i> Very low depth whole genome sequencing in complex trait
716	11.	association studies. 1–24 (2018). doi:10.1101/169789
717	72.	Pasaniuc, B. <i>et al.</i> Extremely low-coverage sequencing and imputation increases
718	12.	power for genome-wide association studies. <i>Nat Genet</i> 44 , 631–635 (2012).
1 10		power for genuine-while association studies. Nat Ushet 44 , 051 -055 (2012).

- 719 73. Martin, A. R., Teferra, S., Möller, M., Hoal, E. G. & Daly, M. J. The critical needs
 720 and challenges for genetic architecture studies in Africa. *Current Opinion in*721 *Genetics & Development* 53, 113–120 (2018).
- 722 74. Coles, E. & Mensah, G. A. Geography of Genetics and Genomics Research 723 Funding in Africa. *Global Heart* **12**, 173–176 (2017).
- 724 75. Mulder, N. J. et al. Development of Bioinformatics Infrastructure for Genomics
- 725 Research. *Global Heart* **12**, 91–98 (2017).